Published ahead of print on September 8, 2005, doi:10.1164/rccm.200505-766OC
American Journal of Respiratory and Critical Care Medicine Vol 172. pp. 1586-1589, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200505-766OC
Transition from Intravenous Epoprostenol to Intravenous Treprostinil in Pulmonary Hypertension
Mardi Gomberg-Maitland,
Victor F. Tapson,
Raymond L. Benza,
Vallerie V. McLaughlin,
Abigail Krichman,
Allison C. Widlitz and
Robyn J. Barst
University of Chicago Hospitals, Chicago, Illinois; Duke University Medical Center, Durham, North Carolina; University of Alabama, Birmingham, Alabama; University of Michigan, Ann Arbor, Michigan; and Columbia University College of Physicians and Surgeons, New York, New York
Correspondence and requests for reprints should be addressed to Mardi Gomberg-Maitland, M.D., M.Sc., Pulmonary Hypertension Center, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 2016, Chicago, IL 60637. E-mail: mgomberg{at}medicine.bsd.uchicago.edu
Rationale: Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension. The prostacyclin analog treprostinil is also efficacious by subcutaneous infusion, is easier to administer, and has a longer half-life. With the demonstration of bioequivalence between subcutaneous and intravenous treprostinil, intravenous treprostinil may have an overall better risk–benefit profile than intravenous epoprostenol.
Objective: To evaluate the safety and efficacy of transitioning patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil.
Methods: Patients enrolled in a 12-wk prospective open label study were switched from intravenous epoprostenol to intravenous treprostinil over 24 to 48 h. The intravenous treprostinil dose was adjusted to minimize symptoms/side effects.
Results: Thirty-one patients (mean age, 43 yr; 22 women) were enrolled. Twenty-seven patients completed the protocol; 4 patients transitioned back to epoprostenol. Six-minute walk distance (n = 27; baseline, 438 ± 16 m; Week 12, 439 ± 16 m), Naughton-Balke treadmill test time (n = 26; baseline, 582 ± 50 s; Week 12, 622 ± 48 s), functional class, and Borg score were maintained with intravenous treprostinil at Week 12 versus intravenous epoprostenol before transition. At Week 12, mean pulmonary artery pressure increased 4 ± 1 mm Hg (n = 27, p < 0.01), cardiac index decreased 0.4 ± 0.1 L/min/m2 (n = 27, p = 0.01), and pulmonary vascular resistance increased 3 ± 1 Wood units · m2 (n = 26, p < 0.01). No serious adverse events were attributed to treprostinil.
Conclusions: These data suggest that transition from intravenous epoprostenol to intravenous treprostinil is safe and effective; whether the hemodynamic differences associated with intravenous treprostinil are clinically important requires longer follow-up.
Key Words: epoprostenol • intravenous treprostinil • pulmonary arterial hypertension
This article has been cited by other articles:
|
|
|
|
 
A. J. Peacock, R. Naeije, N. Galie, and L. Rubin
End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
Eur. Respir. J.,
July 1, 2009;
34(1):
231 - 242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie
Updated evidence-based treatment algorithm in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S78 - S84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al.
End Points and Clinical Trial Design in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
June 30, 2009;
54(1 Suppl):
S97 - 107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1573 - 1619.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al.
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Circulation,
April 28, 2009;
119(16):
2250 - 2294.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. McGoon and G. C. Kane
Pulmonary Hypertension: Diagnosis and Management
Mayo Clin. Proc.,
February 1, 2009;
84(2):
191 - 207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Chin, R. N. Channick, J. A. de Lemos, N. H. Kim, F. Torres, and L. J. Rubin
Hemodynamics and Epoprostenol Use Are Associated With Thrombocytopenia in Pulmonary Arterial Hypertension
Chest,
January 1, 2009;
135(1):
130 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gomberg-Maitland
Traditional and Alternative Designs for Pulmonary Arterial Hypertension Trials
Proceedings of the ATS,
July 15, 2008;
5(5):
610 - 616.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gomberg-Maitland and H. Olschewski
Prostacyclin therapies for the treatment of pulmonary arterial hypertension
Eur. Respir. J.,
April 1, 2008;
31(4):
891 - 901.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Thenappan, S. J. Shah, S. Rich, and M. Gomberg-Maitland
A USA-based registry for pulmonary arterial hypertension: 1982 2006
Eur. Respir. J.,
December 1, 2007;
30(6):
1103 - 1110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Shapiro and N. S. Hill
Transition From IV to Subcutaneous Prostacyclin: Premature Withdrawal?
Chest,
September 1, 2007;
132(3):
741 - 743.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rubenfire, V. V. McLaughlin, R. P. Allen, G. Elliott, M. H. Park, M. Wade, and R. Schilz
Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension: A Controlled Trial
Chest,
September 1, 2007;
132(3):
757 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin
Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines
Chest,
June 1, 2007;
131(6):
1917 - 1928.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Widlitz, S. McDevitt, G. R. Ward, and A. Krichman
Practical Aspects of Continuous Intravenous Treprostinil Therapy
Crit. Care Nurse,
April 1, 2007;
27(2):
41 - 50.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. Barst, N. Galie, R. Naeije, G. Simonneau, R. Jeffs, C. Arneson, and L. J. Rubin
Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
Eur. Respir. J.,
December 1, 2006;
28(6):
1195 - 1203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Steiner, I. R. Preston, J. R. Klinger, G. J. Criner, A. B. Waxman, H. W. Farber, and N. S. Hill
Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
Chest,
November 1, 2006;
130(5):
1471 - 1480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Voswinckel, B. Enke, F. Reichenberger, M. Kohstall, A. Kreckel, S. Krick, H. Gall, T. Gessler, T. Schmehl, H. A. Ghofrani, et al.
Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results From Randomized Controlled Pilot Studies
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1672 - 1681.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gomberg-Maitland
Learning to pair therapies and the expanding matrix for pulmonary arterial hypertension: is more better?
Eur. Respir. J.,
October 1, 2006;
28(4):
683 - 686.
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. V. McLaughlin and M. D. McGoon
Pulmonary Arterial Hypertension
Circulation,
September 26, 2006;
114(13):
1417 - 1431.
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Lang, M. Gomez-Sanchez, M. Kneussl, R. Naeije, P. Escribano, N. Skoro-Sajer, and J.-L. Vachiery
Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension
Chest,
June 1, 2006;
129(6):
1636 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Hoeper and L. J. Rubin
Update in pulmonary hypertension 2005.
Am. J. Respir. Crit. Care Med.,
March 1, 2006;
173(5):
499 - 505.
[Full Text]
[PDF]
|
|
|
Copyright © 2005 American Thoracic Society
|
|
|
